Key result
Aprocitentan reduced TGF-β-induced proliferation rate by ~23% and significantly attenuated mitochondrial reactive oxygen species generation and fragmentation in human cardiac fibroblasts.
Why the study?
Since cardiac fibroblasts express both ETA and ETB receptors, the authors hypothesized that aprocitentan could attenuate TGF-beta-induced proliferation and mitochondrial reactive oxygen species production.
Does aprocitentan reduce TGF-β-induced proliferation and mitochondrial dysfunction in human cardiac fibroblasts?
Does aprocitentan reduce TGF-β-induced proliferation and mitochondrial dysfunction in human cardiac fibroblasts?
Answers are grounded in this paper and cite their sources.
Aprocitentan mitigates TGF-β-induced mitochondrial dysfunction and proliferation in human cardiac fibroblasts, highlighting its potential as an anti-fibrotic therapy in cardiovascular disorders.
Endothelin-1 (ET-1) is a peptide hormone primarily produced by endothelial cells that acts as a potent vasoconstrictor via two receptors, namely ETA and ETB. Although most ET-1 investigations have been focused on endothelial dysfunction and hypertension, mounting evidence has shown that ET-1 is also involved in other physiological processes, including the modulation of cell proliferation, inflammation, and tissue remodelling. Its dysregulation has been implicated in the pathogenesis of several diseases, such as heart failure, atherosclerosis, fibrosis, systemic sclerosis, and carcinogenesis.1–5 Aprocitentan (ACT-132577) is a relatively novel dual ET-1 receptor antagonist that inhibits the binding of ET-1 to both endothelin receptors3; it has been shown to markedly reduce blood pressure in patients with resistant hypertension.1,2,6 Since fibroblasts express both ETA and ETB receptors,4,5,7 we hypothesized that aprocitentan could attenuate proliferation rate and mitochondrial reactive oxygen species (ROS) production induced by transforming growth factor TGF-β (TGF-β) in human cardiac fibroblasts (HCFs). Human cardiac fibroblasts were isolated from human hearts from fully de-identified cadaveric donors (Einstein-Montefiore IRB #20 211 279, PI: Prof. G. Santulli) and cultured in cardiac fibroblast growth medium (Millipore Sigma #316-500). Proliferation rate was measured as we previously described.8 Human cardiac fibroblasts were treated with aprocitentan (Alomone Labs, #A-350, 4 μM) and/or TGF-β1 (PeproTech, #100-21C, 10 ng/mL) for 72 h. The physiological concentration of aprocitentan was calculated based on its molecular weight (546 g/mol) and on the 12.5-g dose used in the PRECISION trial.6 Doses and times were identified in dedicated dose–response and time–course preliminary assays (not shown). Aprocitentan reduced by ∼23% the TGF-β-induced proliferation rate in HCFs (Figure 1A). Then, we sought to investigate whether aprocitentan could mitigate mitochondrial dysfunction. Indeed, the mitochondrion is a main source of ROS, which can promote myofibroblast differentiation. Mitochondrial properties in HCFs were detected by MitoTracker Green and MitoSOX staining, as we previously described.9 Mitochondrial ROS production was triggered by TGF-β treatment and significantly attenuated by aprocitentan (Figure 1B, C); additionally, aprocitentan mitigated mitochondrial fragmentation induced via TGF-β treatment (Figure 1B, D). Aprocitentan significantly reduces proliferation rate (A), generation of mitochondrial reactive oxygen species (B, C), and mitochondrial fragmentation (B, D) induced by TGF-β in human cardiac fibroblasts. The cells were cultured with or without TGF-β or aprocitentan for 72 h. Data are means ± SEM; the violin plots in Panel A represent median and interquartile ranges (dashed lines); the elongation factor is an index of elongated vs. fragmented mitochondria; n ≥ 8; *P < 0.05; **P < 0.01, ****P < 0.005; ****P < 0.001 (ANOVA followed by Bonferroni post hoc correction); representative pictures are reported in Panel B. Our study is not exempt from limitations; for instance, we did not compare the effects of aprocitentan to other ET-1 antagonists, like bosentan, macitentan, and ambrisentan. These drugs are approved for treatment of pulmonary arterial hypertension, which is characterized by vascular remodelling and fibrosis in the pulmonary arteries, and have shown efficacy in improving symptoms, exercise capacity, and hemodynamics1,4; specifically, macitentan has been shown to reduce the progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension.10 Further assays in this sense, ideally accompanied by in vivo experiments, are warranted. To the best of our knowledge, we are the first group to show that aprocitentan can mitigate the increased production of mitochondrial ROS, mitochondrial fragmentation, and cell proliferation rate induced by TGF-β in HCFs. This finding could open new fields of investigation and therapeutic approaches to treat fibrosis in cardiovascular disorders. The Santulli's Laboratory is supported in part by the American Heart Association (24IPA1268813) and by the National Institutes of Health: National Heart, Lung, and Blood Institute (R01-HL146691, T32-HL144456, and T32-HL172255), and the National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK033823 and R01-DK123259). F.V. is supported in part by the American Heart Association (22POST915561 and 24POST1195524). S.S.J. is supported in part by a postdoctoral fellowship of the American Heart Association (21POST836407). U.K. is supported in part by a postdoctoral fellowship of the American Heart Association (23POST1026190). Conflict of interest: no conflict of interest to declare. The data underlying this article will be shared on reasonable request to the corresponding author.
No takes yet. Share an insight, caveat, or question.
Varzideh et al. (2024) studied Fibrosis and mitochondrial oxidative stress. Aprocitentan vs. TGF-β1 alone or vehicle was evaluated on TGF-β-induced proliferation rate and mitochondrial reactive oxygen species production (p=<0.05). Aprocitentan reduced TGF-β-induced proliferation rate by ~23% and significantly attenuated mitochondrial reactive oxygen species generation and fragmentation in human cardiac fibroblasts.
Synapse has enriched 10 related papers. Consider them for comparative context: